Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Hepatocellular carcinoma surveillance: An evidence-based approachWorld Journal of Gastroenterology.  25:1550-1559. 2019
2019 Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With PlaceboClinical Gastroenterology and Hepatology.  17:774-783.e4. 2019
2018 Effect of Hepatitis C Treatment on Renal Function in Liver Transplant Patients.Journal of Clinical and Translational Hepatology.  6:391-395. 2018
2018 Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patientsJGH Open.  2:317-321. 2018
2018 Hepatitis C care cascade among persons born 1945-1965: 3 medical centersAmerican Journal of Managed Care.  24:421-427. 2018
2018 Hepatitis C virus testing for case identification in persons born during 1945-1965: Results from three randomized controlled trialsHepatology.  67:524-533. 2018
2018 Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular CarcinomaClinics in Liver Disease.  22:201-211. 2018
2017 Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplantHepatology International.  11:434-439. 2017
2017 The effect of transjugular intrahepatic portosystemic shunt on platelet counts in patients with liver cirrhosisGastroenterology and Hepatology -New York-.  13:286-291. 2017
2017 Short article: Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: A retrospective study in a large urban tertiary centerEuropean Journal of Gastroenterology and Hepatology.  29:1219-1222. 2017
2017 Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST-C studyHepatology.  65:44-53. 2017
2015 HIV Infection Status as a Predictor of Hepatitis C Virus RNA Testing in Primary CareAmerican Journal of Preventive Medicine.  49:423-427. 2015
2015 Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: Cross-sectional analysis of a multisite retrospective cohort studyClinical Infectious Diseases.  60:1145-1152. 2015
2015 Hepatitis C Virus Testing Perspectives Among Primary Care Physicians in Four Large Primary Care SettingsHealth Promotion Practice.  16:256-263. 2015
2014 Surveillance for hepatocellular carcinoma: Evidence, guidelines and utilizationAmerican Journal of the Medical Sciences.  347:415-419. 2014
2013 Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis CAntiviral Therapy.  18:885-893. 2013
2012 Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseasesHPB.  14:625-634. 2012
2012 The use of sirolimus should be restricted in liver transplantationJournal of Hepatology.  56:288-290. 2012
2011 Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: A proteomic signature validated by enzyme-linked immunosorbent assayLiver Transplantation and Surgery.  17:723-732. 2011
2004 Resolution of Hereditary Hemorrhagic Telangiectasia and Anemia with Prolonged α-interferon Therapy for Chronic Hepatitis CJournal of Clinical Gastroenterology.  38:377-379. 2004
2003 Hemoglobinuria with ribavirin treatmentJournal of Clinical Gastroenterology.  36:367-368. 2003

Chapter

Year Title Altmetric
2014 Variceal hemorrhage.  145-158. 2014

Research Overview

  • Hepatitis C Virus (HCV)
    Nonalcoholic Fatty Liver Disease (NASH)
    Liver transplantation
  • Principal Investigator On

  • Private Grant  awarded by SC LIVER RESEARCH CONSORTIUM 2017 - 2024
  • Private Grant  awarded by TOBIRA THERAPEUTICS 2018 - 2023
  • Private Grant  awarded by INTERCEPT PHARMACEUTICALS 2019 - 2023
  • Private Grant  awarded by CONATUS PHARMACEUTICALS, INC. 2017 - 2021
  • Private Grant  awarded by CONATUS PHARMACEUTICALS, INC. 2016 - 2020
  • Private Grant  awarded by CEPHEID 2015 - 2018
  • Private Grant  awarded by SC LIVER RESEARCH CONSORTIUM 2016 - 2018
  • Private Grant  awarded by SC LIVER RESEARCH CONSORTIUM 2016 - 2018
  • Private Grant  awarded by MERCK & COMPANY, INC. 2016
  • Private Grant  awarded by Gilead Sciences 2016
  • Private Grant  awarded by INTERCEPT PHARMACEUTICALS 2016
  • Private Grant  awarded by CONATUS PHARMACEUTICALS, INC. 2014 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012 - 2016
  • Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C Study (BEST-C) (Phase 2)  awarded by CDC Foundation 2012 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2016
  • Private Grant  awarded by CONATUS PHARMACEUTICALS, INC. 2014
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2010 - 2014
  • Private Grant  awarded by KADMON PHARMACEUTICALS, LLC. 2013
  • Private Grant  awarded by Gilead Sciences 2013
  • Private Grant  awarded by SALIX PHARMACEUTICALS, INC. 2013
  • Private Grant  awarded by Genentech 2012
  • Private Grant  awarded by Gilead Sciences 2012
  • Hepatitis C Virus (HCV) Screening Practices and Prevalence in Primary Care Settings  awarded by RESEARCH TRIANGLE INSTITUTE 2010 - 2012
  • Private Grant  awarded by SC LIVER RESEARCH CONSORTIUM 2011
  • Investigator On

  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC. 2019 - 2023
  • Private Grant  awarded by Gilead Sciences 2015 - 2021
  • Alabama Coalition for Testing, Interventions and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION 2017 - 2020
  • Acute Liver Failure Study Group 13C- Methacetin Breath Test for the Prediction of Acute Liver Failure  awarded by University of Texas Southwestern Medical Center at Dallas 2016 - 2020
  • Private Grant  awarded by MALLINCKRODT, INC. 2017 - 2020
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION 2015 - 2019
  • Private Grant  awarded by ALLERGAN SALES, LLC 2018 - 2019
  • Private Grant  awarded by INTERCEPT PHARMACEUTICALS 2016 - 2018
  • Private Grant  awarded by EISAI, INC. 2016 - 2017
  • Private Grant  awarded by OLYMPUS AMERICA 2016
  • A Phase 2A Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF)  awarded by University of Texas Southwestern Medical Center at Dallas 2015 - 2016
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION 2015 - 2016
  • Private Grant  awarded by SALIX PHARMACEUTICALS, INC. 2013 - 2015
  • Private Grant  awarded by SALIX PHARMACEUTICALS, INC. 2013 - 2015
  • Private Grant  awarded by OCERA THERAPEUTICS, INC. 2013 - 2014
  • Private Grant  awarded by SALIX PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2014
  • Private Grant  awarded by VITAL THERAPIES, INC 2012 - 2014
  • Private Grant  awarded by CLINUVEL PHARMACEUTICALS LTD 2012 - 2014
  • Private Grant  awarded by OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC 2012 - 2013
  • Education And Training

  • Doctor of Philosophy in Internal Medicine Residency Program, Al-Azhar University 1996
  • Bachelor of Medicine & Surgery (MBBS), Al-Azhar University 1982
  • Case Western Reserve University, Internship 2002
  • Case Western Reserve University, Residency 2004
  • Mayo Clinic, Postdoctoral Fellowship 2009
  • Medical College of Wisconsin, Postdoctoral Fellowship 2008
  • Full Name

  • Omar Massoud